+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biogen Inc. - logo

Founded in 1978 Biogen Inc is a global biotechnology company with its headquarters in Cambridge, Massachusetts. In 2003 Biogen merged with Idec Pharmaceuticals to create Biogen Idec and acquired Syntonix Pharmaceuticals in 2007. In 2015 the company returned to its original name Biogen Inc and acquired Convergence Pharmaceuticals. Biogen focuses on drug discovery for a range of conditions including neuropathic pain, hemophilia, organ failure, neuromuscular disorders and oncology. Their product portfolio includes Rituxan, Avonex, Tecfidera and Eloctate.

From
From
From
From
From
Biosimilar Commercial Strategies and Tactics - Product Thumbnail Image

Biosimilar Commercial Strategies and Tactics

  • Report
  • May 2019
  • 67 Pages
  • Global
Neuropathy Pain Treatment Market 2024-2028 - Product Thumbnail Image

Neuropathy Pain Treatment Market 2024-2028

  • Report
  • November 2023
  • 171 Pages
  • Global
From
From
From
Amyotrophic Lateral Sclerosis Treatment Market 2024-2028 - Product Thumbnail Image

Amyotrophic Lateral Sclerosis Treatment Market 2024-2028

  • Report
  • October 2023
  • 157 Pages
  • Global
From
Gene Therapy Market 2024-2028 - Product Thumbnail Image

Gene Therapy Market 2024-2028

  • Report
  • June 2024
  • 177 Pages
  • Global
From
From
Ischemic Stroke - Pipeline Insight, 2025 - Product Thumbnail Image

Ischemic Stroke - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 180 Pages
  • Global
From
Acute Ischemic Stroke- Pipeline Insight, 2025 - Product Thumbnail Image

Acute Ischemic Stroke- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
From
Oligonucleotide Therapeutics Market 2024-2028 - Product Thumbnail Image

Oligonucleotide Therapeutics Market 2024-2028

  • Report
  • April 2024
  • 169 Pages
  • Global
From
Loading Indicator